U Specks, FC Fervenza, TJ McDonald, MC … - Arthritis Care & Research - interscience.wiley.com We report on the successful, compassionate use of the anti-CD20 chimeric
monoclonal antibody rituximab in a patient with chronic, relapsing cytoplasmic
antineutrophil cytoplasmic antibody (cANCA)-associated Wegener's ... Cited by 212 - Related articles - BL Direct - All 5 versions
- ►atsjournals.org KA Keogh, SR Ytterberg, FC Fervenza, KA … - American journal of respiratory and critical care …, 2006 - Am Thoracic Soc Methods: A prospective open-label pilot trial was conducted with 10 patients
monitored for 1 yr. Included were patients with active severe antineutrophil
cytoplasmic antibody (ANCA)–associated vasculitis, ANCA positivity, and ... Cited by 195 - Related articles - BL Direct - All 8 versions
JLM Ferrara, P Reddy - Seminars in hematology, 2006 - Elsevier Complications of allogeneic hematopoietic stem cell transplantation (HSCT)
remain barriers to its wider application for a variety of diseases.
Graft-versus-host disease (GVHD) is the major cause of morbidity and ... Cited by 184 - Related articles - All 10 versions
- ►hematologylibrary.org - Free from Publisher M Zecca, P De Stefano, B Nobili, F Locatelli - Blood, 2001 - bloodjournal.hematologylibrary.org An 18-month-old Caucasian girl was hospitalized due to recent onset of pallor
and listlessness. Physical examination at admission was unremarkable, with the
exception of pallor and mild jaundice; the patient did not present either ... Cited by 127 - Related articles - BL Direct - All 5 versions
- ►haematologica-thj.org [PDF] F Zaja, I Iacona, P Masolini, D Russo, A … - Haematologica, 2002 - haematologica-thj.org Background and Objectives. Rituximab reacts specifically with the CD20 antigen
and induces B- cell depletion. This could interfere with the produc- tion of
autoantibodies in some immune diseases. The objective of this study was to ... Cited by 121 - Related articles - BL Direct - All 15 versions
- ►bloodjournal.org LE van der Kolk, JW Baars, MH Prins, MHJ … - Blood, 2002 - Am Soc Hematology The present immunization study was part of a phase I/II study evaluating the
safety and efficacy of the combination of rituximab (375 mg/m 2 weekly for 4
weeks) and granulocyte-colony-stimulating factor (G-CSF; 5 µg/kg per day, ... Cited by 120 - Related articles - BL Direct - All 5 versions
CA Vieira, A Agarwal, BK Book, RA Sidner, … - Transplantation, 2004 - journals.lww.com Vieira, Carlos A.; Agarwal, Avinash; Book, Benita K.; Sidner, Richard A.;
Bearden, Christopher M.; Gebel, Howard M.; Roggero, Anthony L.; Fineberg, Naomi
S.; Taber, Timothy; Kraus, Michael A.; Pescovitz, Mark D. Cited by 116 - Related articles - BL Direct - All 3 versions
- ►bloodjournal.org C Cutler, D Miklos, HT Kim, N Treister, SB Woo … - Blood, 2006 - Am Soc Hematology B cells may be implicated in the pathophysiology of chronic graft-versus-host
disease (GVHD), as evidenced by antibody production against sex-mismatched, Y
chromosome–encoded minor HLA antigens in association with chronic GVHD. ... Cited by 112 - Related articles - BL Direct - All 6 versions
V Ratanatharathorn, L Ayash, C Reynolds, S … - Biology of Blood and Marrow Transplantation, 2003 - Elsevier We reviewed the clinical outcome of 8 patients with steroid-refractory chronic
graft-versus-host disease (GVHD) who received an anti-CD20 chimeric monoclonal
antibody (rituximab). Rituximab was given by intravenous infusion at a ... Cited by 100 - Related articles - BL Direct - All 5 versions
